Welcome to our dedicated page for Izotropic Canada news (Ticker: IZOZF), a resource for investors and traders seeking the latest updates and insights on Izotropic Canada stock.
Izotropic Canada (IZOZF) specializes in advanced breast imaging technology designed to improve cancer detection in dense breast tissue. This news hub provides investors and healthcare professionals with official updates on regulatory progress, clinical developments, and corporate milestones.
Access timely press releases covering FDA communications, European regulatory strategies, and peer-reviewed study results. Our curated collection includes updates on the IzoView Breast CT system's commercialization efforts, partnership announcements, and financial disclosures.
Key content categories include regulatory filings, clinical trial updates, technology enhancements, and strategic collaborations. All materials are sourced directly from the company to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to critical updates about Izotropic's innovative diagnostic solutions. Check regularly for new developments in contrast-enhanced imaging technology and market expansion initiatives.
Izotropic (IZOZF) has announced several key corporate updates. The company has engaged JG Global Communications as its International Communications Consultant for a 6-month term at $6,000 monthly, with the consultant receiving 200,000 stock options at $0.31 and 200,000 RSUs.
The company granted additional equity awards totaling 3,000,000 stock options at CAD $0.31 and 300,000 RSUs to directors, officers, and consultants.
Additionally, Izotropic amended its loan agreement with 0914474 BC The loan balance has increased to CAD $2,675,000, reflecting accrued interest and extension fees. The loan carries a 12% annual interest rate, payable quarterly, with the next maturity date set for September 30, 2025. As part of the amendment, 3,000,000 bonus warrants were issued at $0.31 per share with a 5-year term.
Izotropic (OTCQB: IZOZF) has completed its pre-submission meeting with the FDA on March 20, 2025, regarding its IzoView Breast CT Imaging System. The meeting focused on advancing the regulatory strategy for breast cancer screening indication.
The discussion involved key stakeholders including Izotropic's executive leadership, technical teams, medical advisors, and FDA representatives. Critical topics addressed included clinical protocol synopsis, radiation dose considerations, and the management of breast cancers detected by IzoView but not visible through digital breast tomosynthesis.
According to FDA Consultant Dr. Kyle Myers, the discussion was positive, with most of Izotropic's clinical data collection and study design approaches aligning with FDA expectations. Research indicates the technology's benefit in detecting additional cancers is approximately 10 times the relative risk from radiation exposure to patients.
Izotropic (OTCQB: IZOZF) has announced that CEO Robert Thast will present at the Life Sciences Virtual Investor Conference on March 13th, 2025, from 11:00-11:30am PST. The presentation will showcase the company's IzoView Breast CT system and its potential impact in the breast imaging market.
The presentation comes amid projections showing the global breast imaging device market is expected to grow from $5.40 billion in 2024 to $8.69 billion by 2030. The U.S. market specifically is forecast to expand from $1.01 billion to $1.55 billion during the same period.
The conference presentation will cover:
- IzoView's competitive advantages
- Company expansion strategy
- Potential revenue models
- Customer ROI analysis
Izotropic (OTCQB: IZOZF) announces that the FDA has scheduled a pre-submission meeting for March 20, 2025, regarding the clinical study design for its IzoView Breast CT Imaging System. The company plans to launch IzoView with contrast-enhancement as an adjunctive screening tool to 3D mammography, specifically targeting patients with dense breast tissue.
Dense breast tissue, affecting approximately 50% of U.S. women, is both a risk factor for breast cancer and makes standard screening methods less effective. The technology, developed at UC Davis Medical Center, has demonstrated promising results through four successive breast CT systems tested in clinical trials. Izotropic holds exclusive global licensing rights to this technology, which has been supported by peer-reviewed scientific research.
Izotropic (OTCQB: IZOZF) has announced the rescheduling of its investor conference presentation from February 6th to March 13th, 2025, due to a family emergency affecting the CEO's availability. The presentation will now take place at the OTC's Life Science Virtual Investor Forum.
The company, which specializes in medical device development for breast cancer screening and diagnosis, confirmed that its business plans and progress remain unaffected, with the CEO expected to resume normal business operations next week. One-on-one meetings previously scheduled with the CEO will be rearranged directly with affected parties.
Izotropic (OTCQB: IZOZF) has announced its upcoming presentation at the Small Cap Growth Virtual Investor Conference on February 6, 2025. CEO Robert Thast will present from 3:00-3:30 PM EST, discussing the company's recent achievements, regulatory approvals in the U.S. and EU, near-term objectives, and funding options.
This marks the company's first public presentation since revealing its new regulatory strategy for U.S. FDA approval and timeline for launching IzoView, their dedicated breast CT imaging system. The device features contrast-enhancement for breast cancer screening, working alongside 3D mammography for patients with dense breast tissue.
The virtual conference will include a live Q&A session, and attendance is complimentary for individual and institutional investors, advisors, and analysts. Those unable to attend can access an archived webcast of the presentation.
Izotropic has outlined its timeline and milestones for the FDA approval and launch of IzoView Breast CT Imaging System. The company's strategy focuses on dense breast tissue imaging, with a modular clinical study design that reduces PMA submission time by approximately 6 months. The plan includes a 3-site U.S.-based clinical study, which will also facilitate early data collection for European CE Mark Application.
The company has structured its path to market in 7 key phases: Prepare IzoView, Site Setup, Clinical Study, Reader Study, Modular Submissions, PMA Application, and Approval and Sales. Additionally, Izotropic plans to announce the development of two new medical imaging devices within the next 12 months to build momentum and enhance valuation during the clinical data collection phase.
Izotropic has been featured in Research and Markets' analysis of the U.S. breast cancer screening and diagnostic market. The report projects market growth from $1.55 billion in 2024 to $2.34 billion by 2030, with a 7.05% CAGR.
The company's IzoView Breast CT system offers true 3D breast imaging without compression, completing scans in 10 seconds with radiation doses comparable to 2-view mammography. This technology addresses limitations in current screening methods, particularly for dense breast tissue patients who comprise 50% of U.S. women. The system can detect lesions as small as 2mm when used with contrast enhancement, potentially offering 1¼ years earlier detection compared to traditional mammography, which typically finds 11mm tumors.
Digital breast tomosynthesis (DBT) currently leads the market with a 49.93% share as of 2023, though it still faces challenges in detecting cancers in dense breast tissue.
Izotropic has announced key appointments to lead its clinical study design and FDA regulatory submissions for IzoView, its dedicated breast CT imaging system. The team includes Dr. Kyle J. Myers, former FDA Director of Imaging, Diagnostics, and Software Reliability; Dr. Alicia Toledano, former Deputy Director of ACRIN's Biostatistics Center; and John DeLucia, former VP of Regulatory Affairs at iCAD.
The team has developed a regulatory strategy and clinical study design for IzoView, which aims to serve as an adjunctive tool to digital breast tomosynthesis for breast cancer screening in asymptomatic women with dense breast tissue. This initiative targets approximately 50% of the U.S. breast cancer screening population who have dense breasts and are currently underserved by standard imaging modalities.
Izotropic has filed a pre-submission with the U.S. FDA for its IzoView Breast CT Imaging System, targeting breast cancer screening in women with dense breast tissue as an adjunct to 3D mammography. The company's strategic approach aims to increase potential annual IzoView scans market size by over 800%.
The comprehensive 60-page filing includes clinical study plans projecting a 2.5-year timeline at an approximate cost of USD 3.5 million. IzoView offers high-resolution true 3D imaging with 100 times greater spatial resolution than MRI, potentially detecting lesions and tumors as small as 2mm when used with contrast enhancement. The system operates without painful breast compression and produces approximately 500 high-resolution images in 10 seconds.
The clinical study will involve 3 sites and includes a 1-year negative cancer case validation period. The company awaits FDA's confirmation of the pre-submission meeting date within their 75-day processing window.
